In LGG, PRAD, and THCA, however, the negative connection between CRHBP and ICP genes revealed that low CRHBP expression might be predictive of inferior immunotherapeutic results when targeting ICP genes. This evidence concerns the gene CRHBP and prostate adenocarcinoma.